Trial · NCT00668434

Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica

NCT00668434, Phase 2, Completed, Kaiser Permanente; results first posted 2015-04-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica. Trials, record NCT00668434. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00668434

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica
NCT number: NCT00668434
Status: Completed
Phases: Phase 2
Enrollment: 269 participants, actual
Lead sponsor: Kaiser Permanente
Conditions: Sciatica
Interventions: Prednisone, Placebo
First posted: 2008-04-29
Last updated: 2015-04-28
Results first posted: 2015-04-28

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Oswestry Disability Index, v2	Baseline, Week 3 follow-up	The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.
Secondary	Pain Numerical Rating Scale	Baseline, Week 3 follow-up	Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.
Secondary	Oswestry Disability Index, v2	Baseline, Week 52 follow-up	The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.
Secondary	Pain Numerical Rating Scale	Baseline, Week 52 follow-up	Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Oswestry Disability Index, v2	Baseline, Week 3 follow-up	units on a scale	MEAN
SECONDARY	Pain Numerical Rating Scale	Baseline, Week 3 follow-up	units on a scale	MEAN
SECONDARY	Oswestry Disability Index, v2	Baseline, Week 52 follow-up	units on a scale	MEAN
SECONDARY	Pain Numerical Rating Scale	Baseline, Week 52 follow-up	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Oswestry Disability Index, v2	Prednisone	-19.0	Standard Error 1.4	units on a scale
Oswestry Disability Index, v2	Placebo	-13.3	Standard Error 1.7	units on a scale
Pain Numerical Rating Scale	Prednisone	-3.0	Standard Error 0.2	units on a scale
Pain Numerical Rating Scale	Placebo	-2.8	Standard Error 0.3	units on a scale
Oswestry Disability Index, v2	Prednisone	-37.8	Standard Error 1.5	units on a scale
Oswestry Disability Index, v2	Placebo	-30.4	Standard Error 2.2	units on a scale
Pain Numerical Rating Scale	Prednisone	-5.2	Standard Error 0.2	units on a scale
Pain Numerical Rating Scale	Placebo	-4.6	Standard Error 0.3	units on a scale

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Primary Outcome Time Point (3 Weeks)	STARTED	Prednisone	181
Primary Outcome Time Point (3 Weeks)	STARTED	Placebo	88
Primary Outcome Time Point (3 Weeks)	COMPLETED	Prednisone	179
Primary Outcome Time Point (3 Weeks)	COMPLETED	Placebo	88
Primary Outcome Time Point (3 Weeks)	NOT COMPLETED	Prednisone	2
Primary Outcome Time Point (3 Weeks)	NOT COMPLETED	Placebo	0
Secondary Outcome Time Point (52 Weeks)	STARTED	Prednisone	179
Secondary Outcome Time Point (52 Weeks)	STARTED	Placebo	88
Secondary Outcome Time Point (52 Weeks)	COMPLETED	Prednisone	157
Secondary Outcome Time Point (52 Weeks)	COMPLETED	Placebo	77

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events30

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Cardiovascular problem	Cardiac disorders	Prednisone	3	181	4
other	Cardiovascular problem	Cardiac disorders	Placebo	0	88	0
other	Dermatologic problem	Skin and subcutaneous tissue disorders	Prednisone	18	181	56
other	Dermatologic problem	Skin and subcutaneous tissue disorders	Placebo	10	88	27
other	Ear or eye disorder	Ear and labyrinth disorders	Prednisone	0	181	0
other	Ear or eye disorder	Ear and labyrinth disorders	Placebo	2	88	6
other	Gastrointestinal problem	Gastrointestinal disorders	Prednisone	41	181	85
other	Gastrointestinal problem	Gastrointestinal disorders	Placebo	8	88	32
other	Genitourinary problem	Renal and urinary disorders	Prednisone	3	181	8
other	Genitourinary problem	Renal and urinary disorders	Placebo	2	88	8

1 to 10 of 30Source ClinicalTrials.gov

See all 30 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Prednisone
Total, all-cause mortality	Placebo
Total, other adverse events	Prednisone	143	181
Total, other adverse events	Placebo	63	88
Total, serious adverse events	Prednisone	3	181
Total, serious adverse events	Placebo	2	88

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
25988461	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01AR053960	Steroid Delivery in Acute Herniated Lumbar Disc with Radiculopathy	GOLDBERG, HARLEY	KAISER FOUNDATION RESEARCH INSTITUTE	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES	2007 to 2011

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Prednisone vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00668434

GET https://conductscience.org/api/trials/v1/NCT00668434/events?page=2

API reference For AI assistants